What's new? Log in Free sign up

Sonnet BioTherapeutics (SONN)

Company Profile

Company profile

Ticker

SONN

Exchange

Website

www.sonnetbio.com

CEO

Dr. Pankaj Mohan Ph.D.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris • AbbVie • Bausch Health Companies ...

Former names

Chanticleer Holdings, Inc., TULVINE SYSTEMS INC

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Sonnet BioTherapeutics, Inc. • Sonnet BioTherapeutics CH SA • SonnetBio Pty Ltd ...

IRS number

522102141

SONN stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Chardan Capital

Latest filings (excl ownership)

View all

Regulation FD Disclosure

Regulation FD Disclosure

Quarterly report

Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update

Notice of effectiveness

Notice of effectiveness

Prospectus supplement

Prospectus supplement

IPO registration (amended)

30 Jan 25

IPO registration (amended)

30 Jan 25

Latest ownership filings

View all

STEPHEN J MCANDREW

Albert D. Dyrness

Donald J. Griffith

Richard T Kenney

Financial summary

Financial statements Chart SONN financial data

Quarter (USD)	Dec 24	Sep 24	Jun 24	Mar 24
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Sep 24	Sep 23	Sep 22	Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q3 2024

SONN institutional ownership history Ownership history

0.0% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	2	2	–
Opened positions	2	2	–
Closed positions	2	1	+100.0%
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	2.97 mm	15.69 mm	-81.1%
Total shares	443.00	49.39 k	-99.1%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Tower Research Capital	378.00	$2.53 mm	NEW
BlackRock	65.00	$435.00 k	NEW
Proequities	0.00	$0.00
Private Wealth Management	0.00	$3.00 k

Largest transactions	Shares	Bought/sold	Change
Virtu Financial	0.00	-32.69 k	EXIT
Geode Capital Management	0.00	-16.70 k	EXIT
Tower Research Capital	378.00	+378.00	NEW
BlackRock	65.00	+65.00	NEW
Proequities	0.00	0.00
Private Wealth Management	0.00	0.00

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

SONN insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
11 Dec 23	Dyrness Albert D.	Common Stock	Grant	Acquire A	No	No	0	373	0.00	537
11 Dec 23	Raghu Rao	Common Stock	Grant	Acquire A	No	No	0	373	0.00	2,356
11 Dec 23	Nailesh Bhatt	Common Stock	Grant	Acquire A	No	No	0	373	0.00	547
11 Dec 23	Susan Dexter	Common Stock	Grant	Acquire A	No	No	0	1,452	0.00	1,643

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Sonnet BioTherapeutics Q1 EPS $(1.56) Misses $(1.39) Estimate

Sonnet BioTherapeutics (NASDAQ:SONN) reported quarterly losses of $(1.56) per share which missed the analyst consensus estimate of $(1.39) by 12.23 percent. This is a 36.59 percent increase over losses of $(2.46) per

European Patent Office Grants Sonnet BioTherapeutics Patent No. EP3583125 B1, Entitled "Albumin Binding Domain Fusion Proteins,"

European Patent Office (EPO) grants EU Patent No. EP3583125 B1 covering the Company's Fully Human Albumin Binding (FHAB®) domain fusion proteinsIn addition to the U.S. and EU, Sonnet's global IP coveragenow extends

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Sonnet BioTherapeutics Has Been Granted European Patent Number EP3583125 Titled "ALBUMIN BINDING DOMAIN FUSION PROTEINS (FOR THE TREATMENT OF CANCER)".

Sonnet Expands Phase 1 SB101 Study Of SON-1010, Combining With Trabectedin In Advanced Soft-Tissue Sarcoma; Enrollment Of 18 Patients Expected By H1 2025; Topline Safety Data Due H2 2025; Monotherapy Suggested Clinical Benefit; Potential Phase 2 Study Envisioned

Press releases

From Benzinga Pro

Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates

Building on proven targeting of the FHAB domain, Sonnet's ADC platform offers flexible payload capacity and controllable drug-antibody ratios (DAR) An epidermal growth factor receptor 2 (HER2) ADC construct designated

Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference

PRINCETON, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the "Company" or "Sonnet") (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced

Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer

PRINCETON, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs,

Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update

Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.